BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien Thema: Hauptdiskussion

Ist einer von euch auch bei fosun pharmaceutical drin?

Hat sich whitehours heute gemeldet ?

Jetzt aber all in Short 😂😂

Dir auch🙏

In kombi erklärt das den anstieg

Männer komm gerade vom Tennis, war eine gute Einheit. Biontech stark, schönes Wochenende

Das oben schon, das unten sprich der link ist zum impfstoff

Gregels ist so wie ich das lese ne Nachricht zu einem anderen Medikament aber positiv nebenbei!

Ande, du hast dich nun hier öffentlich blamiert herzlichen Glückwunsch

Ande, du hast dich nun hier öffentlich blamiert herzlichen Glückwunsch

Und hier die Nachrichten aus china https://www.boerse-online.de/nachrichten/aktien/biontech-erhaelt-in-china-gruenes-licht-fuer-corona-impfstoff-studie-1029400020

Ist das die Meldung, auf die wir alle gewartet haben?

, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, announced today that the first-in-human Phase I/IIa study with DuoBody-PD-L1x4-1BB has been initiated. DuoBody PD-L1x4-1BB is a bispecific antibody in joint development with Genmab A/S, which is being studied in patients with metastatic or unresectable malignant solid tumors, who are not candidates for standard therapy. DuoBody-PD-L1x4-1BB is the first product candidate from the companies’ worldwide 50% cost-sharing 50% profit-sharing collaboration to enter the clinic. The objective of the collaboration, signed in 2015 and expanded in 2016 to include additional targets and technologies, is to develop and commercialize multiple novel bispecific antibodies with superior in vivo efficacy that specifically activate the immune system against cancer cells. “The achievement of starting a Phase I/IIa clinical trial with a product candidate developed in only four years is a validation of our highly productive partnership with Genmab,” said Prof. Ugur Sahin, CEO of BioNTech. “DuoBody-PD-L1x4-1BB’s pan-cancer, dual-immuno-stimulatory mode of action contributes an additional layer of treatment options to our overall cancer pipeline. It also serves BioNTech’s strategy of exploiting novel targets and mechanisms to harness the full potential of the immune system for cancer immunotherapy.” DuoBody-PD-L1x4-1BB is a novel bispecific antibody that combines checkpoint blockade of the inhibitory PD-1:PD-L1 signaling axis with conditional stimulation of T cells by activation of the 4-1BB receptor, thereby enhancing the proliferation of activated T cells to efficiently target cancer cells. The original idea and concept for this approach to combine immune-brake removing (PD-L1) and acceleration properties (4-1BB) to combat cancer are based on research conducted at BioNTech. The open-label safety trial of DuoBody-PD-L1x4-1BB (ClinicalTrials.gov Identifier NCT03917381) consists of two parts: a dose escalation part (Phase I, first-in-human) and an expansion part (Phase IIa). As primary endpoint, the multi-center trial will foremost assess safety including dose limiting toxicity and adverse events.

Bin raus, ist mir zu heikel.

Doch, die gab es, mein short ist schon geschlossen, und wenn du ernsthaft denkst man könnte den Kurs bei einem Börsen News Forum runter reden solltest du vielleicht nicht in Aktien investieren.

Posetive News aus China gabs heute nicht. Ich habe den Eindruck das Gregels den Kurs runterreden will weil er Short gegangen ist.